Cefprozil 500mg tablets

Introduction and objective: A rising number of group A streptococcal infections has been observed all over Europe since 2022. In addition to the high number of patients, the increase in the proportion of progressive, severe, invasive cases has been noticed as an alarming problem. The aim of our study was to describe the characteristics of the Hungarian Streptococcus pyogenes epidemic in the paediatric primary care setting, based on a questionnaire covering a large cohort of paediatric patients. Methods: A 21-item structured questionnaire was sent out on the general physician network platform to primary care paediatricians nationwide in May 2024. The questionnaire was retrospective, assessing actual diagnostic and treatment strategies for streptococcal diseases identified between 1 January and 31 December 2023. Results: Based on data from a total of 71,600 children in 72 paediatric practices, 8.5% (95% confidence interval: 7.1–9.9%) of the enrolled children were diagnosed with streptococcal tonsillitis and/or scarlet fever (n = 6110), of which a quarter of the infected children (2.1%; 95% confidence interval: 1.74–2.46%) showed symptoms of scarlet fever (n = 1515). 82% of the patients were in the age group 5–10 years. Peritonsillar abscesses developed in 0.6% of patients (41 cases), invasive disease was diagnosed in 9 children, post-streptococcal glomerulonephritis occurred in 2 children, while reinfection was observed in an average of 15%. In nearly half of the suspected cases (47%), diagnostic microbiological tests were carried out. In terms of therapeutic strategy, the most commonly used antibiotic was amoxicillin-clavulanic acid (41%), but the combined use of narrower spectrum beta-lactams (penicillin, amoxicillin, cefprozil) reached 50%. Macrolide was used by 6%, cefixime by 3%. Discussion: In the current streptococcal epidemic point-of-care diagnosis, early recognition of invasive diseases and appropriate antibiotic selection are crucial for both clinical outcome and antibiotic stewardship. Our results suggest that greater use of rapid testing and the promotion of early, narrow-spectrum antibiotic treatment in proven cases should be encouraged. Conclusion: Our study provides feedback to primary care paediatricians on diagnostic and therapeutic practices and emphasizes the importance of adequate antibiotic selection and early recognition of invasive S. pyogenes infections. Orv Hetil. 2025; 166(19): 719–727.

Abstract licence: CC BY

To the editor, X-linked immunodeficiency with magnesium defect, Epstein-Barr virus (EBV) infection, and neoplasia (XMEN) is a rare primary immunodeficiency caused by mutations in the magnesium transporter 1 (MAGT1) gene [1,2].Due to its rarity and variable clinical course, each case offers valuable insight into this complex condition.A 29-year-old male presented with fever, jaundice, and fatigue.He had a childhood history of idiopathic thrombocytopenic purpura (ITP) and surgery for patent ductus arteriosus.Laboratory tests showed severe anemia (Hb: 4.6 g/dL), mild thrombocytopenia, indirect hyperbilirubinemia, elevated lactate dehydrogenase, C-reactive protein (CRP), and undetectable haptoglobin.The direct Coombs test was negative, and schistocytes were noted on peripheral smear.Thrombotic microangiopathy (TMA) was suspected, but paroxysmal nocturnal hemoglobinuria (PNH) and ADAMTS13 tests were normal.He received plasmapheresis and corticosteroids without benefit.Eculizumab was initiated for suspected atypical hemolytic uremic syndrome (aHUS), leading to hematologic improvement.Bone marrow biopsy showed erythroid hyperplasia with dyserythropoiesis.Computed tomography (CT) examination revealed pathologic axillary lymphadenopathy.Biopsy confirmed EBV-positive nodular lymphocyte predominant Hodgkin lymphoma (Stage 3A), treated with six cycles of R-CHOP, achieving remission.About 2.5 years after the initial presentation, he developed Coombs-positive autoimmune hemolytic anemia (AIHA) with thrombocytopenia.Steroids were ineffective; eltrombopag and rituximab were given.Cytomegalovirus (CMV) reactivation was treated with ganciclovir.Rituximab resolved cytopenias.Approximately 2 years later, severe hemolysis recurred after cefprozil.Rituximab was resumed but paused due to CMV reactivation, which was managed with valacyclovir.About 7 months later, hemolytic anemia relapsed.Azathioprine was started.Thrombocytopenia recurred with infections but responded to intravenous immunoglobulin (IVIG).Due to persistent EBV DNA positivity, as determined by PCR, and thrombocytopenia, eltrombopag was reinitiated.The summary of the treatment course is presented in Figure 1 .Recurrent cytopenias and frequent infections prompted an evaluation for underlying immunodeficiency.Serum immunoglobulin levels and subclasses were decreased (IgG1: 3.4 g/L; IgG2: 1.46 g/L).Family history revealed that the patient's brother had developed gait disturbance, ataxia, and dysarthria following a COVID-19 infection at the age of 26.Genetic analysis of the brother identified a hemizygous X-linked MAGT1 mutation and a heterozygous autosomal dominant COL4A1 mutation.The asymptomatic mother was heterozygous for the same MAGT1 variant.Genetic testing of the patient confirmed a hemizygous MAGT1 mutation (Figure 1).Flow cytometry revealed a CD4/CD8 ratio of 1.1.Serum magnesium concentrations in our case were consistently within normal limits.Hemoglobin and platelet counts returned to normal without further eltrombopag therapy.No evidence of lymphoma recurrence was observed.The patient was initiated on IVIG therapy every 21 days and placed under regular follow-up.Although the diagnostic criteria for XMEN disease have not yet been fully standardized, they can be summarized based on reported cases in the literature and current clinical guidelines.The diagnosis of XMEN disease is based on the identification of a loss-of-function mutation in the MAGT1 gene, which is located on the X chromosome.Hemizygous mutations are typically seen in males, while heterozygous female carriers are usually asymptomatic.Immunological findings often include CD4+ T-cell lymphopenia, impaired T-cell activation, decreased intracellular magnesium levels, and reduced surface expression of the NKG2D receptor on CD8 T cells and NK cells [1].Clinically, affected individuals may present with persistent or chronic EBV viremia, EBV-related lymphoproliferative disorders , recurrent infections and autoimmune cytopenias [3].Additional features may include dysgammaglobulinemia, lymphadenopathy, and splenomegaly.A decreased CD4/CD8 ratio and

Abstract licence: CC BY-NC-ND

BACKGROUND Foreign body aspiration (FBA) is a common and serious problem in childhood that requires early recognition and treatment. Common complications include asphyxia, hemorrhage, infection, and pneumothorax. In severe cases of foreign body obstruction, death can result from asphyxia. We report an interesting case in which a forgotten cotton ball was inhaled into the lungs. CASE REPORT A 5-year-old boy presented to the local hospital with coughing for 6 days and fever for 4 days, without any information of foreign body aspiration upon admission. Laboratory findings indicated an elevated white blood cell; therefore, cefprozil was given as anti-infective treatment. However, the child's condition did not improve. A computed tomography scan showed left pulmonary atelectasis. Considering that the child's condition was serious, he was referred to our hospital for diagnosis and treatment. After referral, auscultation revealed decreased breath sounds over the left lung. After multidisciplinary discussion, combined with the results of auxiliary examination, the possibility of a foreign body was considered. He underwent rigid bronchoscopy, which confirmed a yellow-white foreign body in the left main bronchus that was later verified as a cotton ball. The operation was very successful. Eventually, his condition improved and he was discharged, without additional complications. CONCLUSIONS For children with unclear history of foreign body aspiration, bronchoscopy is recommended if there is recurrent pulmonary infection, low auscultation breath sounds, or abnormal imaging. The choice of surgical method depends on the location and type of foreign body and the experience of the surgeon, which is also very important.

Abstract licence: CC BY-NC-ND

The dengue virus (DENV) infects approximately 400 million people annually worldwide causing significant morbidity and mortality. Despite advances in understanding the virus life cycle and infectivity, no specific treatment for this disease exists due to the lack of therapeutic drugs. In addition, vaccines available currently are ineffective with severe side effects. Therefore, there is an urgent need for developing therapeutics suitable for effective management of DENV infection. In this study, we adopted a drug repurposing strategy to identify new therapeutic use of existing FDA approved drug molecules to target DENV2 non-structural proteins NS3 and NS5 using computational approaches. We used Drugbank database molecules for virtual screening and multiple docking analysis against a total of four domains, the NS3 protease and helicase domains and NS5 MTase and RdRp domains. Subsequently, MD simulations and MM-PBSA analysis were performed to validate the intrinsic atomic interactions and the binding affinities. Furthermore, the internal dynamics in all four protein domains, in presence of drug molecule binding were assessed using essential dynamics and free energy landscape analyses, which were further coupled with conformational dynamics-based clustering studies and cross-correlation analysis to map the regions that exhibit these structural variations. Our comprehensive analysis identified tolcapone, cefprozil, delavirdine and indinavir as potential inhibitors of NS5 MTase, NS5 RdRp, NS3 protease and NS3 helicase functions, respectively. These high-confidence candidate molecules will be useful for developing effective anti-DENV therapy to combat dengue infection.

Abstract licence: CC BY

Staphylococcus epidermidis is a coagulase-negative staphylococcus (CoNS) and an opportunistic pathogen, particularly in patients with compromised immune systems or indwelling medical devices. This study aimed to isolate, identify, and characterize S. epidermidis from human and animal pus samples, assessing its antibiotic resistance profiles. Out of total 250 pus samples, comprising 200 human and 50 animal samples, the prevalence of S. epidermidis was 10% (N=20) in human samples and 34% (N=17) in animal samples, yielding an overall prevalence of 14.08%. The presence of the mecA gene, responsible for methicillin resistance, was detected in 43% of isolates, and the fnbA gene, associated with biofilm formation, was found in 22% of the isolates. Antibiotic susceptibility testing against 59 antimicrobial drugs revealed a high prevalence of resistance to β-lactam antibiotics, particularly cefuroxime (90% in humans, 82.35% in animals), cefmetazole (80% in humans, 88.24% in animals), cephalothin (75% in humans, 88.24% in animals), cefprozil (85% in humans, 76.47% in animals), and cefonicid (75% in humans, 88.24% in animals). Significant resistance was also observed against methicillin and oxacillin, with resistance rates of 60% and 50% in humans, and 52.94% and 70.59% in animals, respectively. Aminoglycosides, such as gentamycin and tobramycin, exhibited moderate resistance, particularly in human isolates. In contrast, vancomycin showed strong activity against both human (75%) and animal (82.35%) isolates, highlighting its effectiveness for treating S. epidermidis infections. Sparfloxacin and levofloxacin, among the fluoroquinolones, demonstrated better efficacy, with high susceptibility observed, particularly in humans. Macrolides, especially azithromycin and erythromycin, showed poor activity, with high resistance observed in both, 90% and 55% in human isolates and 58.82% and 41.18% among animal isolates, respectively. These findings underscore the growing concern of antimicrobial resistance in S. epidermidis , especially in β-lactam, macrolides and aminoglycoside classes, and emphasize the need for careful antibiotic selection, with vancomycin and levofloxacin being promising options for treatment. These findings underscore the growing concern of multidrug-resistant S. epidermidis , particularly in clinical and veterinary settings and highlight the need of rigorous surveillance and antibiotic stewardship in managing S. epidermidis related infections. • The prevalence of S. epidermidis in human and animal samples were 10% and 34% respectively, with an overall prevalence of 14.08%. • The S. epidermidis isolates showed high resistance to β-lactam and macrolide group of antibiotics and moderate resistance to aminoglycosides. • More than 50% of the isolates were found to be methicillin resistant and 22% isolates showed biofilm formation associated gene (fnbA). • The isolates showed high susceptibility to Sparfloxacin (86.49), Vancomycin (78.38%) and Levofloxacin (75.68%). • The growing multidrug-resistant S. epidermidis , stresses the need for antibiotic stewardship and surveillance in both human and veterinary medicine.

Abstract licence: CC BY-NC-ND